Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
122,545,605
-
Shares change
-
-14,673,081
-
Total reported value, excl. options
-
$245,076,906
-
Value change
-
-$37,929,778
-
Put/Call ratio
-
14.31%
-
Number of buys
-
75
-
Number of sells
-
-61
-
Price
-
$2
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q1 2020
163 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q1 2020.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122,545,605 shares
of 209,618,986 outstanding shares and own 58.46% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13,395,617 shares), BAKER BROS. ADVISORS LP (10,946,166 shares), VANGUARD GROUP INC (8,772,116 shares), Eversept Partners, LP (7,542,372 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (7,500,000 shares), MILLENNIUM MANAGEMENT LLC (6,452,341 shares), CITADEL ADVISORS LLC (6,109,534 shares), STATE STREET CORP (5,746,052 shares), UBS Group AG (5,083,238 shares), and JANUS HENDERSON GROUP PLC (4,877,731 shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.